Adial Pharmaceuticals receives FDA alignment on Phase 3 trial design for AD04 in alcohol use disorder

ADIAL PHARMACEUTICALS, INC.

FDA End-of-Phase 2 meeting held July 29, 2025; final minutes received confirming alignment on adaptive Phase 3 design.
FDA confirmed primary endpoint of zero heavy drinking days during months 5 and 6 of efficacy observation.
FDA supported biomarker stratification (AG+ subgroup, ~14% of general population) and adaptive enrichment strategy.
FDA advised pre-specifying key secondary endpoints in protocol for potential future product labeling.
CEO highlights new patent filing that may extend AD04 market exclusivity to 2045.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.